The drugmaker said the deal’s potential value is over $1 billion.
Founded in 2015, Pasadena, Calif.-based Protomer has built a portfolio of therapeutic candidates, with glucose-responsive insulins being chief among them.
“Glucose-sensing insulin is the next frontier and has the potential to revolutionize the treatment and quality of life of people with diabetes by dramatically improving both therapeutic efficacy and safety of insulin therapy,” Ruth Gimeno, PhD, Eli Lilly’s vice president of diabetes research and clinical investigation said in a news release. “Protomer’s glucose-sensing insulin program, based on its proprietary molecular engineering of protein sensors platform, is showing significant promise and Lilly is excited to enhance our diabetes pipeline with the company’s innovative technology.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
